{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:19:36Z","timestamp":1790223576405,"version":"4.1.0"},"reference-count":47,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Individual patient data (IPD)-based meta-analysis (ACCRUE, meta-analysis of cell-based cardiac studies, NCT01098591) revealed an insufficient effect of intracoronary cell-based therapy in acute myocardial infarction. Patients with ischemic heart failure (iHF) have been treated with reparative cells using percutaneous endocardial, surgical, transvenous or intracoronary cell delivery methods, with variable effects in small randomized or cohort studies. The objective of this meta-analysis was to investigate the safety and efficacy of percutaneous transendocardial cell therapy in patients with iHF. Two investigators extracted the data. Individual patient data (IPD) (n = 8 studies) and publication-based (n = 10 studies) aggregate data were combined for the meta-analysis, including patients (n = 1715) with chronic iHF. The data are reported in accordance with PRISMA guidelines. The primary safety and efficacy endpoints were all-cause mortality and changes in global ejection fraction. The secondary safety and efficacy endpoints were major adverse events, hospitalization and changes in end-diastolic and end-systolic volumes. Post hoc analyses were performed using the IPD of eight studies to find predictive factors for treatment safety and efficacy. Cell therapy was significantly (p &lt; 0.001) in favor of survival, major adverse events and hospitalization during follow-up. A forest plot analysis showed that cell therapy presents a significant benefit of increasing ejection fraction with a mean change of 2.51% (95% CI: 0.48; 4.54) between groups and of significantly decreasing end-systolic volume. The analysis of IPD data showed an improvement in the NYHA and CCS classes. Cell therapy significantly decreased the end-systolic volume in male patients; in patients with diabetes mellitus, hypertension or hyperlipidemia; and in those with previous myocardial infarction and baseline ejection fraction \u2264 45%. The catheter-based transendocardial delivery of regenerative cells proved to be safe and effective for improving mortality and cardiac performance. The greatest benefit was observed in male patients with significant atherosclerotic co-morbidities.<\/jats:p>","DOI":"10.3390\/jcm11113205","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T09:42:32Z","timestamp":1654335752000},"page":"3205","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Meta-Analysis of Percutaneous Endomyocardial Cell Therapy in Patients with Ischemic Heart Failure by Combination of Individual Patient Data (IPD) of ACCRUE and Publication-Based Aggregate Data"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7083-2107","authenticated-orcid":false,"given":"Mariann","family":"Gy\u00f6ngy\u00f6si","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9494-4234","authenticated-orcid":false,"given":"Evgeny","family":"Pokushalov","sequence":"additional","affiliation":[{"name":"Center of the New and Modern Medical Technologies, 630090 Novosibirsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Romanov","sequence":"additional","affiliation":[{"name":"E. Meshalkin National Medical Research Center, 630055 Novosibirsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3622-9814","authenticated-orcid":false,"given":"Emerson","family":"Perin","sequence":"additional","affiliation":[{"name":"Stem Cell Center and Adult Cardiology, Texas Heart Institute, Houston, TX 37660, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7751-5032","authenticated-orcid":false,"given":"Joshua M.","family":"Hare","sequence":"additional","affiliation":[{"name":"Interdisciplinary Stem Cell Institute, Cardiovascular Division, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kastrup","sequence":"additional","affiliation":[{"name":"Cardiology Stem Cell Centre, The Centre for Cardiac, Vascular, Pulmonary and Infectious Diseases, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Fern\u00e1ndez-Avil\u00e9s","sequence":"additional","affiliation":[{"name":"CIBERCV, Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3370-6064","authenticated-orcid":false,"given":"Ricardo","family":"Sanz-Ruiz","sequence":"additional","affiliation":[{"name":"CIBERCV, Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Mathur","sequence":"additional","affiliation":[{"name":"Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojcieh","family":"Wojakowski","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, 40-635 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enca","family":"Martin-Rendon","sequence":"additional","affiliation":[{"name":"R&D Division, National Health Service (NHS)-Blood and Transplant, Oxford Centre, Oxford OX3 9DU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Pavo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imre J.","family":"Pavo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayyan","family":"Hemetsberger","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8679-1525","authenticated-orcid":false,"given":"Denise","family":"Traxler","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-0361","authenticated-orcid":false,"given":"Andreas","family":"Spannbauer","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7714-4446","authenticated-orcid":false,"given":"Paul M.","family":"Haller","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Heart and Vascular Center UKE Hamburg, 20246 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1161\/CIRCRESAHA.116.304346","article-title":"Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data","volume":"116","author":"Gyongyosi","year":"2015","journal-title":"Circ. Res."},{"key":"ref_2","first-page":"CD007888.pub3","article-title":"Stem cell therapy for chronic ischaemic heart disease and congestive heart failure","volume":"12","author":"Fisher","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1161\/CIRCRESAHA.115.307347","article-title":"Meta-Analyses of Human Cell-Based Cardiac Regeneration Therapies","volume":"118","author":"Wojakowski","year":"2016","journal-title":"Circ. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1093\/eurheartj\/ehaa651","article-title":"The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: The BAMI trial","volume":"41","author":"Mathur","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/ehf2.13256","article-title":"Reparative cell therapy for the heart: Critical internal appraisal of the field in response to recent controversies","volume":"8","author":"Povsic","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41587-019-0042-1","article-title":"Regenerating the field of cardiovascular cell therapy","volume":"37","author":"Chien","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/jamacardio.2018.4435","article-title":"A Time to Press Reset and Regenerate Cardiac Stem Cell Biology","volume":"4","author":"Epstein","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/CIRCRESAHA.118.311208","article-title":"New Myocyte Formation in the Adult Heart","volume":"123","author":"Vagnozzi","year":"2018","journal-title":"Circ. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ncpcardio1388","article-title":"Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: The MYSTAR prospective, randomized study","volume":"6","author":"Lang","year":"2009","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12265-009-9123-8","article-title":"Efficiency of intramyocardial injections of autologous bone marrow mononuclear cells in patients with ischemic heart failure: A randomized study","volume":"3","author":"Pokushalov","year":"2010","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ahj.2011.01.028","article-title":"A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF)","volume":"161","author":"Perin","year":"2011","journal-title":"Am. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1001\/jama.2012.418","article-title":"Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: The FOCUS-CCTRN trial","volume":"307","author":"Perin","year":"2012","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ahj.2014.03.022","article-title":"Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial","volume":"168","author":"Perin","year":"2014","journal-title":"Am. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jama.2013.282909","article-title":"Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-HFT randomized trial","volume":"311","author":"Heldman","year":"2014","journal-title":"Jama"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1093\/eurheartj\/ehv136","article-title":"Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: A randomized placebo-controlled trial (MSC-HF trial)","volume":"36","author":"Mathiasen","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ejhf.676","article-title":"An exploratory randomized control study of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with ischaemic cardiomyopathy: The REGENERATE-IHD clinical trial","volume":"19","author":"Choudhury","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jacc.2013.02.071","article-title":"Cardiopoietic stem cell therapy in heart failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics","volume":"61","author":"Bartunek","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_18","first-page":"648","article-title":"Cardiopoietic cell therapy for advanced ischaemic heart failure: Results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial","volume":"38","author":"Bartunek","year":"2017","journal-title":"Eur. Heart. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jcin.2008.11.003","article-title":"One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study)","volume":"2","author":"Dib","year":"2009","journal-title":"JACC. Cardiovasc. Interv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/CIRCRESAHA.115.306332","article-title":"A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure","volume":"117","author":"Perin","year":"2015","journal-title":"Circ. Res."},{"key":"ref_21","first-page":"805","article-title":"Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: The SEISMIC trial","volume":"6","author":"Duckers","year":"2011","journal-title":"Eur. J. EuroPCR Collab. Work. Group Interv. Cardiol. Eur. Soc. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ahj.2011.07.020","article-title":"A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction","volume":"162","author":"Povsic","year":"2011","journal-title":"Am. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/S0140-6736(16)30137-4","article-title":"Ixmyelocel-T for patients with ischaemic heart failure: A prospective randomised double-blind trial","volume":"387","author":"Patel","year":"2016","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ejhf.2178","article-title":"A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: The CCTRN CONCERT-HF trial","volume":"23","author":"Bolli","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_25","unstructured":"Perin, E.C. (2022, May 31). Randomized Trial of Targeted Transendocardial Delivery of Mesenchymal Precursor Cells in High-Risk Chronic Heart Failure Patients with Reduced Ejection Fraction\u2014The Dream-Hf Trial. Available online: https:\/\/www.acc.org\/education-and-meetings\/image-and-slide-gallery\/~\/media\/507EF21A5AA945178E2705FAB2A4FA1F.pdf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2018s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ejhf.1412","article-title":"Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE)","volume":"21","author":"Paitazoglou","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_28","first-page":"e5585","article-title":"Efficacy and Safety of Stem Cell Therapy in Advanced Heart Failure Patients: A Systematic Review with a Meta-analysis of Recent Trials Between 2017 and 2019","volume":"11","author":"Jayaraj","year":"2019","journal-title":"Cureus"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13287-019-1258-1","article-title":"Efficacy of mesenchymal stem cell therapy in systolic heart failure: A systematic review and meta-analysis","volume":"10","author":"Fan","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00059-018-4762-7","article-title":"Mesenchymal stem cell therapy for heart failure: A meta-analysis","volume":"45","author":"Fu","year":"2020","journal-title":"Herz"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1161\/CIRCRESAHA.116.304386","article-title":"Meta-analysis of cell therapy trials for patients with heart failure","volume":"116","author":"Fisher","year":"2015","journal-title":"Circ. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.atherosclerosis.2014.01.027","article-title":"Intramyocardial autologous bone marrow cell transplantation for ischemic heart disease: A systematic review and meta-analysis of randomized controlled trials","volume":"233","author":"Tian","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cjca.2014.01.013","article-title":"Autologous transplantation of bone marrow\/blood-derived cells for chronic ischemic heart disease: A systematic review and meta-analysis","volume":"30","author":"Xu","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.12659\/MSM.892047","article-title":"Efficacy and Safety of Bone Marrow Cell Transplantation for Chronic Ischemic Heart Disease: A Meta-Analysis","volume":"20","author":"Xiao","year":"2014","journal-title":"Med. Sci. Monit."},{"key":"ref_35","first-page":"Cd007888","article-title":"Stem cell therapy for chronic ischaemic heart disease and congestive heart failure","volume":"12","author":"Fisher","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.hlc.2013.04.112","article-title":"Intramyocardial autologous cell engraftment in patients with ischaemic heart failure: A meta-analysis of randomised controlled trials","volume":"22","author":"Cheng","year":"2013","journal-title":"Heart Lung Circ."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.amjcard.2013.03.021","article-title":"Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy","volume":"112","author":"Kandala","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1517\/14712598.2012.721764","article-title":"Bone marrow-derived mononuclear cell therapy for patients with ischemic heart disease and ischemic heart failure","volume":"12","author":"Wen","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1517\/14712598.2011.616491","article-title":"Additive value of adult bone-marrow-derived cell transplantation to conventional revascularization in chronic ischemic heart disease: A systemic review and meta-analysis","volume":"11","author":"Zhao","year":"2011","journal-title":"Expert Opin. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jtcvs.2010.12.013","article-title":"Intramyocardial bone marrow stem cell transplantation during coronary artery bypass surgery: A meta-analysis","volume":"142","author":"Donndorf","year":"2011","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jcmg.2010.04.012","article-title":"Imaging the migration of therapeutically delivered cardiac stem cells","volume":"3","author":"Hemetsberger","year":"2010","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrcardio.2011.64","article-title":"Diagnostic and prognostic value of 3D NOGA mapping in ischemic heart disease","volume":"8","author":"Gyongyosi","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_44","first-page":"e46","article-title":"Heart disease and stroke statistics--2010 update: A report from the American Heart Association","volume":"121","author":"Adams","year":"2010","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cardfail.2008.10.006","article-title":"Six minute walk test predicts long-term all-cause mortality and heart failure rehospitalization in African-American patients hospitalized with acute decompensated heart failure","volume":"15","author":"Alahdab","year":"2009","journal-title":"J. Card. Fail."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/pr.2017.249","article-title":"Strategies to enhance paracrine potency of transplanted mesenchymal stem cells in intractable neonatal disorders","volume":"83","author":"Park","year":"2018","journal-title":"Pediatric Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12031-018-1070-x","article-title":"Mesenchymal Stem Cells Form 3D Clusters Following Intraventricular Transplantation","volume":"65","author":"Jungwirth","year":"2018","journal-title":"J. Mol. Neurosci."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/11\/3205\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:24:30Z","timestamp":1760138670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/11\/3205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,4]]},"references-count":47,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["jcm11113205"],"URL":"https:\/\/doi.org\/10.3390\/jcm11113205","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,4]]}}}